Literature DB >> 7796873

Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine.

Y Y Glinka1, M B Youdim.   

Abstract

The enzymes of mitochondrial respiratory chain, NADH dehydrogenase (complex I) and cytochrome c oxidase (complex IV), were completely inhibited by 6-hydroxydopamine with IC50 = 10.5 microM and IC50 = 34 microM respectively. The enzyme inhibition was insensitive to the change of NADH or cytochrome c concentrations. The extent of complex I inhibition decreased as a consequence of both non-enzymatic and monoamine oxidase-catalyzed oxidation of 6-hydroxydopamine. Monoamine oxidase A and B inhibitors, tranylcypromine and clorgyline but not l-deprenyl increased the extent of 6-hydroxydopamine induced inhibition of complex I. Thus, 6-hydroxydopamine itself and not its oxidation products may be responsible for the neurotoxicity of this agent via inhibition of respiratory chain enzymes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796873     DOI: 10.1016/0926-6917(95)90040-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  58 in total

1.  Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease.

Authors:  S M Kulich; C T Chu
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

2.  EPC-K1, a hydroxyl radical scavenger, prevents 6-hydroxydopamine-induced dopamine depletion in the mouse striatum by up-regulation of catalase activity.

Authors:  H Kabuto; I Yokoi; E Iwata-Ichikawa; N Ogawa
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 3.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

4.  Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease.

Authors:  Sofía Sánchez-Iglesias; Pablo Rey; Estefanía Méndez-Alvarez; José Luis Labandeira-García; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2006-12-12       Impact factor: 3.996

5.  Differential involvement of mitochondrial permeability transition in cytotoxicity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine.

Authors:  Chung Soo Lee; Woo Jae Park; Hyun Hee Ko; Eun Sook Han
Journal:  Mol Cell Biochem       Date:  2006-04-20       Impact factor: 3.396

6.  Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons.

Authors:  J Lotharius; L L Dugan; K L O'Malley
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

Review 7.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.

Authors:  Jun Tang Guo; An Qi Chen; Qi Kong; Hua Zhu; Chun Mei Ma; Chuan Qin
Journal:  Cell Mol Neurobiol       Date:  2007-11-06       Impact factor: 5.046

9.  Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains.

Authors:  Jason Callio; Tim D Oury; Charleen T Chu
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

10.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.